Xcout Intel
SpliSense competitors & alternatives
The 12 closest competitors and alternatives to SpliSense among biotechnology companies — ranked by similarity to what SpliSense actually does, not by market-cap band.
Subscribe to see SpliSense’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About SpliSense
SpliSense is an Israeli biotechnology company developing antisense oligonucleotide therapies that correct disease-causing RNA splicing defects. Its programs are aimed at patients with genetic diseases, including specific mutations associated with cystic fibrosis.
SpliSense at a glance
SpliSense is a biotechnology company headquartered in Israel, founded in 2016. It has raised at least $41.5M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $13M in June 2026. Xcout tracks 8 named people at SpliSense, including Gili Hart (CEO).
SpliSense leadership
- Gili HartCEO
- Lior BuchmanCEO at Integra Holdings
- Batsheva KeremChief Scientist
- Dr. Nissim DarvishChairman, Venture Partner at Orbimed & Managing General Partner at MeOhr Ventures
- Dr. Stanley FielRegional Chairman of Medicine at Atlantic Health
- Ido ZairiGeneral Partner at Israel Biotech Fund
2 more named people on record for SpliSense, with roles, board committees and tenure — see the full roster →
SpliSense funding rounds
At least $41.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $13M | 4 named | |
| Series B | $28.5M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 SpliSense competitors
Ranked by semantic similarity — how close each company is to SpliSense by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Skip Therapeutics is an Israeli biotechnology company founded in 2021 and based in Ness Ziona. The company develops personalized RNA-based therapies, including antisense oligonucleotides, for rare genetic disorders and common diseases using a proprietary computational discovery engine.
Biotech
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Biotech
Sionna Therapeutics is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, focused on developing treatments for cystic fibrosis.
Similar biotechnology company
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Biotech
Rznomics is a South Korean biotechnology company developing RNA-based gene therapies using a trans-splicing ribozyme platform. Its programs are focused primarily on therapeutic applications in cancer and other serious diseases, serving patients through prospective drug-development and clinical partnerships.
Similar biotechnology company
Dynacure is a biotechnology company developing antisense oligonucleotide therapies for rare neuromuscular diseases. Its lead program, DYN101, targets DNM2-associated centronuclear myopathy for patients with this serious inherited muscle disorder.
Similar biotechnology company
Lorem Technologies Inc. (n-Lorem Foundation) applies antisense technology to charitably develop and provide experimental antisense oligonucleotide (ASO) medicines for patients with nano-rare diseases caused by unique single gene mutations. The organization serves patients, physicians, and institutions by offering personalized treatments and professional clinical management at no cost.
Similar biotechnology company
BreezeBio is a biotechnology company headquartered in the South San Francisco area of California that develops precision genetic medicines.
Biotech
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Similar biotechnology company
Creyon Bio is a biotechnology organization that engineers RNA-based and oligonucleotide medicines designed to enable tissue-specific delivery with improved safety and efficacy.
Similar biotechnology company
Switch Therapeutics Inc. is a biotechnology company headquartered in South San Francisco, California. Founded in 2020, the company develops RNAi therapies based on its proprietary technology.
Biotech
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of SpliSense and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for SpliSenseand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →